

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2563)

INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE FULL CIRCULATION OF SHARES BY THE COMPANY

This announcement is made by Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules, namely under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

References are made to the announcement (the “**Announcement**”) of the Company dated 6 February 2026 in relation to the issuance of filing notice by the CSRC of the Application. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

The Company has applied to the Listing Committee of the Stock Exchange for the approval of the listing of and permission to deal in 147,867,143 H Shares (the “**Converted H Shares**”) to be converted from 147,867,143 Unlisted Shares. The Board is pleased to announce that the listing approval was granted by the Stock Exchange on 20 March 2026 (the “**Listing Approval**”).

SHAREHOLDING STRUCTURE OF THE COMPANY BEFORE AND AFTER THE COMPLETION OF THE CONVERSION AND LISTING

The Conversion and Listing will involve a total of 20 participating shareholders (the “**Participating Shareholders**”) holding 147,867,143 Unlisted Shares, which will, after the Conversion and Listing, represent approximately 40.6% of the total issued Shares of the Company. Set out below is the shareholding percentage of the Participating Shareholders upon completion of the Conversion and Listing.

No.	Name of the Participating Shareholders	Number of Converted H Shares	Approximate percentage of total issued Shares upon completion of the Conversion and Listing ^{Note}
1.	SDIC (Shanghai) Technology Transfer Venture Capital Fund Enterprise (Limited Partnership) 國投(上海)科技成果轉化創業投資基金企業(有限合夥)	29,426,685	8.1%
2.	Baygen QT Inc.	20,252,942	5.6%
3.	Beijing Chongde Hongxin Venture Capital Center (Limited Partnership) 北京崇德弘信創業投資中心(有限合夥)	15,529,256	4.3%
4.	Shanghai Haidai Botai Enterprise Management Center (Limited Partnership) 上海海岱帛泰企業管理中心(有限合夥)	12,237,963	3.4%
5.	Zhuhai Jingrong Haoyuan Investment Partnership (Limited Partnership) (珠海京蓉昊緣投資合夥企業(有限合夥))	12,235,689	3.4%
6.	Zhuhai Huajin Haoyuan Enterprise Management Partnership (Limited Partnership) 珠海華錦昊緣企業管理合夥企業(有限合夥)	11,532,518	3.2%
7.	Betta Pharmaceuticals Co., Ltd. 貝達藥業股份有限公司	11,118,045	3.1%
8.	Zhuhai Huaxin Haoyuan Commercial Management Partnership (Limited Partnership) 珠海華欣昊緣商業管理合夥企業(有限合夥)	8,401,220	2.3%
9.	Shanghai Xinhengdeyuan Enterprise Management Center (Limited Partnership) 上海馨升德源企業管理中心(有限合夥)	6,798,296	1.9%
10.	Beijing Zhongling Yanyuan Venture Capital Center (Limited Partnership) 北京中嶺燕園創業投資中心(有限合夥)	3,335,415	0.9%
11.	Nanjing Gaoke Xinjun Growth Phase I Equity Investment Partnership (Limited Partnership) 南京高科新浚成長一期股權投資合夥企業(有限合夥)	3,186,158	0.9%
12.	Chengdu Innovation Venture Capital Co., Ltd. 成都創新風險投資有限公司	3,122,434	0.9%
13.	Zhuhai Huarong Haoyuan Enterprise Management Partnership (Limited Partnership) 珠海華蓉昊緣企業管理合夥企業(有限合夥)	3,000,434	0.8%
14.	Dr. Tang Li (唐莉)	2,155,759	0.6%
15.	Tianjin Tianchuang Yongxin Enterprise Management Partnership (Limited Partnership) 天津天創湧鑫企業管理合夥企業(有限合夥)	1,948,863	0.5%
16.	Chengdu Jingrong Venture Capital Co., Ltd. 成都菁融創業投資有限公司	1,274,465	0.3%
17.	Foshan Hongtao Tongxuan Equity Investment Partnership (Limited Partnership) 佛山弘陶同選股權投資合夥企業(有限合夥)	1,039,696	0.3%
18.	Sichuan Xintongde Big Data Industry Venture Capital Partnership (Limited Partnership) 四川新同德大數據產業創業投資合夥企業(有限合夥)	955,849	0.3%
19.	Beijing Beijinyuan Technology Co., Ltd. 北京北進緣科技有限公司	251,737	0.1%
20.	Chengdu Chengchuang Zhilian Technology Partnership (Limited Partnership) 成都成創智聯科技合夥企業(有限合夥)	63,719	0.0%
Total		147,867,143	40.6%

Note: the calculation is based on a total of 364,588,000 Shares in issue as at the date of this announcement.

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is set out below:

Description of Shares	As at the date of this announcement and immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	<i>Number of Shares</i>	<i>Approximate percentage</i>	<i>Number of Shares</i>	<i>Approximate percentage</i>
Unlisted Shares	147,867,143	40.6%	—	—
H Shares	<u>216,720,857</u>	<u>59.4%</u>	<u>364,588,000</u>	<u>100.0%</u>
Total	<u><u>364,588,000</u></u>	<u><u>100.0%</u></u>	<u><u>364,588,000</u></u>	<u><u>100.0%</u></u>

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
 北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairman and Executive Director

Beijing, the PRC, 30 March 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.